Puerarin inhibits Benign prostatic hyperplasia through regulating HIF-1α-HIF-1β/ AKT1/AP-1
- 8 April 2026
- journal article
- Published by Elsevier in Translational Research
- Vol. 292, 1-13
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (YG2022QN066)
- Shanghai Jiao Tong University (YG2024QNB17)
- National Natural Science Foundation of China (82170788)
This publication has 23 references indexed in Scilit:
- Therapeutic potential of pomegranate juice-derived nanovesicles in nude mouse benign prostatic hyperplasia (BPH) xenograft modelScientific Reports, 2023
- A study on puerarin in situ gel eye drops: Formulation optimization and pharmacokinetics on rabbits by microdialysisInternational Journal of Pharmaceutics, 2023
- Efficacy of puerarin in rats with focal cerebral ischemia through modulation of the SIRT1/HIF-1α/VEGF signaling pathway and its effect on synaptic plasticityHeliyon, 2023
- Puerarin: A review of its mechanisms of action and clinical studies in ophthalmologyPhytomedicine, 2022
- Relationship between severity of obstructive sleep apnea and benign prostatic hyperplasiaSleep and Breathing, 2022
- The role of hypoxia‐inducible factor 1‐alpha in inflammatory bowel diseaseCell Biology International, 2021
- Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP‐1 transcription factor networkThe Prostate, 2014
- Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Protective effect of puerarin on diabetic retinopathy in ratsMolecular Biology Reports, 2008
- Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostateThe Prostate, 1998